CBT and Third-Wave Therapies in Inflammatory Bowel Disease: can we heal the gut by improving mood?
Presenter: Professor Antonina Mikocka-Walus
Deakin University
Can CBT play a role in supporting people living with inflammatory gut conditions such as Crohn’s and ulcerative colitis?
This presentation will discuss current insights into the role and evidence behind CBT and third-wave therapies as part of integrated care for inflammatory bowel diseases.
Inflammatory bowel disease (IBD) involves an abnormal immune response to healthy gut bacteria. The most common forms of IBD are Crohn’s disease and ulcerative colitis. Key IBD-related symptoms include chronic pain, bloody diarrhoea with frequent bowel movements, weight loss, anaemia, and fatigue, causing significant impairments in daily functioning. Bi-directional gut-brain links are considered part of the pathophysiology of IBD; when a person develops IBD, their susceptibility to anxiety and/or depression increases. Up to 66% of individuals report symptoms during an active disease phase. IBD is negatively affected by mental disorders, resulting in more frequent flare-ups, a more aggressive presentation, increased rates of hospital readmissions and increased risk of surgery. Psychological interventions are becoming more commonly tested for different outcomes in IBD and are increasingly incorporated into usual care in gastroenterology clinics.
About this event:
This event will a PowerPoint presentation in an informal setting.
The presentation will review the current evidence base in relation to CBT, ACT, mindfulness and other third wave therapies tested in this context to date on biopsychosocial outcomes. It will also provide an overview of how these therapies can support usual medical care as part of integrated care in gastroenterology.
Key Learning Objectives
Understand the role of CBT and third-wave therapies in the management of IBD
Understand the role of psychology in integrated care for IBD
Learn about the current evidence base for psychological treatment in IBD
This session is designed for those with a casual familiarity – attendees will be assumed to have basic experience in the topic area.
Duration & Format / Training Modalities
This session has approx. 60 minutes CPD, and does not include any catering in the ticket price.
Please note, the venue will be following all relevant Public Health Orders and checking delegates as per their obligations. Density, and mask requirements will be in line with relevant government guidelines. As per all events, please do not attend if you are unwell.
If you are required to cancel your attendance owing to a COVID isolation, please contact us for a full refund or ticket transfer.
Venue notes:
There is street parking outside the venue, plus public transport via 86 tram, and train at Victoria Park. The Victoria Park train station is an 8-minute walk to the venue and is on the Mernda and Hurstbridge lines.
Images: supplied
Speaker Bio
Professor
Antonina Mikocka-Walus
Antonina Mikocka-Walus is a registered psychologist and Professor in Health Psychology at Deakin University. In the last 17 years, she has developed a program of interdisciplinary research in GastroPsychology and is currently in the top 2% of most cited researchers in this area worldwide, with >170 research publications. Antonina’s research has provided robust evidence of the relationship...more about Antonina Mikocka-Walus
Antonina Mikocka-Walus, Professor
Antonina Mikocka-Walus is a registered psychologist and Professor in Health Psychology at Deakin University. In the last 17 years, she has developed a program of interdisciplinary research in GastroPsychology and is currently in the top 2% of most cited researchers in this area worldwide, with >170 research publications. Antonina’s research has provided robust evidence of the relationship between anxiety, depression and disease activity in inflammatory bowel disease. She has developed and tested multiple psychological interventions to support people living with Crohn’s and colitis. Her studies into CBT for IBD have been included in international guidelines for treatment of IBD in Australia, the UK and the US.